Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits

British Journal of Pharmacology

Volumn 119, Issue 6, 1996, Pages 1269-1275

  Mitani, Hironobu ^a   Bandoh, Tsutomu ^a   Ishikawa, Junji ^a   Kimura, Masaaki ^a   Totsuka, Tetsuya ^a   Hayashi, Shigehiro ^a  

^a Sandoz Tsukuba Research Institute   (Japan)

Author keywords

Atherosclerosis; Enalapril; Fluvastatin; HMG CoA reductase inhibitor; Hyperlipidaemic rabbits; Lipid peroxidation; Renin angiotensin system; Vascular angiotensin converting enzyme

Indexed keywords

ACETYLCHOLINE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID PEROXIDE; PHOSPHOLIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ARCH; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERLIPIDEMIA; LIPID PEROXIDATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THORACIC AORTA; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0029903829     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb16032.x     Document Type: Article

References (39)

1. ABERG, G. & FERRER, P. (1990). Effects of captopril on atherosclerosis in cynomolgus monkeys. J. Cardiovasc. Pharmacol., 15, (Suppl. 5), S65-S72.
2. BANDOH, T., MITANI, H., NIIHASHI, M., KUSUMI, Y., ISHIKAWA, J., KIMURA, M., TOTSUKA, T., SAKURAI, I. & HAYASHI, S. (1996). Inhibitory effect of fluvastatin on intimai thickening following balloon catheterization at doses insufficient to lower serum lipids. In 66th Congress of The European Atherosclerosis Society, Florence (Italy) July 1996, p. 117.
3. BERNINI, F., SCURATI, N., BONFADINI, G. & FUMAGALLI, R. (1995). HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler. Thromb. Vasc. Biol., 15, 1352-1358.
4. BRADFORD, M.M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
5. CHOBANIAN, A.V., HAUDENSCHILD, C.C., NICKERSON, C. & DRAGO, R. (1990). Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension, 15, 327-331.
6. CORSINI, A., MAGGI, F.M. & CATAPANO, A.L. (1995a). Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res., 31, 9-27.
7. CORSINI, A., RAITERI, M., SOMA, M.R., BERNINI, F., FUMAGALLI, R. & PAOLETTI, R. (1995b). Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am. J. Cardiol., 76, 21A-28A.
8. DAEMEN, M.J.A.P., LOMBARDI, D.M., BOSMAN, F.T. & SCHWARTZ, S.M. (1991). Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ. Res., 68, 450-456.
9. DAVIDSON, M.H. (1994). FLUENT Investigation group. Fluvastatin long-term extension trial (FLUENT): summary of efficacy and safety. Am. J. Med., 96, 4IS-44S.
10. DZAU, V.J. (1993a). Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic. Res. Cardiol., 88, (Suppl. 1), 1-14.
11. DZAU, V.J. (1993b). Vascular renin-angiotensin system and vascular protection. J. Cardiovasc. Pharmacol., 22 (Suppl. 5), S1-S9.
12. FENNESSY, P.A., CAMPBELL, J.H. & CAMPBELL, G.R. (1994). Perindopril inhibits both the development of atherosclerosis in the cholesterol-fed rabbit and lipoprotein binding to smooth muscle cells in culture. Atherosclerosis, 106, 29-41.
13. FINTA, K.M., FISCHER, M.J., LEE, L., GORDON, D., PITT, B. & WEBB, R.C. (1993). Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet. Atherosclerosis, 100, 149-156.
14. GIROUX, L.M., DAVIGNON, J. & NARUSZEWICZ, M. (1993). Simvastatin inhibits the oxidation of low-density lipoproteins by activated human monocyte-derived macrophages. Biochim. Biophys. Acta, 1165, 335-338.
15. KEIDAR, S., KAPLAN, M. & AVIRAM, M. (1996). Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler. Thromb. Vasc. Biol., 16, 97-105.
16. KEIDAR, A., KAPLAN, M., HOFFMAN, A.A. & AVIRAM, M. (1995). Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis, 115, 201-215.
17. KIMURA, M., KUROSE, I., RUSSELL, J., GRISHAM, M.B. & GRANGER, D.N. (1996). Effects of fluvastatin on leukocyte-endothelial cell interactions in hypercholesterolemic rat. FASEB J., 10, A611.
18. KIMURA, M., MAEDA, K., HARASAWA, Y., OHNO, Y., NAKAMURA, M., SAKURAI, I. & HAYASHI, S. (1992). Recovery of endothelium-dependent responses by reseeding endothelial cells in culture onto the denuded coronary artery. J. Pharmacol. Exp. Ther., 262, 841-849.
19. KOWALA, M.C., GROVE, R.I. & ABERG, G. (1994). Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduced plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis, 108, 61-72.
20. LINZ, W., WIEMER, G., GOHLKE, P., UNGER, T. & SCHOLKENS, B.A. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol. Rev., 47, 25-49.
21. LIPID RESEARCH CLINICS PROGRAM. (1984). The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. J. Am. Med. Ass., 251, 365-374.
22. MAK, LT., FREEDMAN, A.M., DICKENS, B.F. & WEGLICKI, W.B. (1990). Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem. Pharmacol., 40, 2169-2175.
23. MITANI, H., BANDOH, T., KIMURA, M., TOTSUKA, T. & HAYASHI, S. (1996). Increased activity of vascular angiotensin converting enzyme related to atherosclerotic lesions in hyperlipidemic rabbits. Am. J. Physiol., (in press).
24. MIYAZAKI, M., OKUNISHI, H., OKAMURA, T. & TODA, N. (1984). Vascular angiotensin-converting enzyme activity in man and other species. Clin. Sci., 66, 39-45.
25. MIYAZAKI, M., OKUNISHI, H., OKAMURA, T. & TODA, N. (1987). Elevated vascular angiotensin converting enzyme in chronic two-kidney, one clip hypertension in the dog. J. Hypertens., 5, 155-160.
26. MORISHITA, R., GIBBONS, G.H., ELLISON, K.E., LEE, W., ZHANG, L., YU, H., KANEDA, Y., OGIHARA, T. & DZAU, V.J. (1994). Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J. Clin. Invest., 94, 978-984.
27. OSTERRIEDER, W., MULLER, R.K.M., POWELL, J.S., CLOZEL, J.-P., HEFTI, F. & BAUMGARTNER, H.R. (1991). Role of angiotensin II in injury-induced neointima formation in rats. Hypertension, 18 (Suppl. II), II-60-II-64.
28. OVERTURF, M., SYBERS, H., SCHAPER, J. & TAEGTMEYER, H. (1986). Hypertension and atherosclerosis in cholesterol fed rabbits. Atherosclerosis, 59, 283-299.
29. PLOSKER, G.L. & WAGSTAFF, A.J. (1996). Fluvastatin. A review of its pharmacology and use in the management of hypercholesterolaemia. Drugs, 51, 433-459.
30. POWELL, J.S., CLOZEL, J.-P., MULLER, R.K.M., KUHN, H., HEFTI, F., HOSANG, M. & BAUMGARTNER, H.R. (1989). Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science, 245, 186-188.
31. RAICUGl, H., WANG, D.S., DZAU, V.J. & PRATT, R.E. (1994). Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation, 90, 449-455.
32. SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP. (1994). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383-1389.
33. SCHUH, J.R., BLEHM, D.J., FRIERDICH, G.E., MCMAHON, E.G. & BLAINE, E.H. (1993). Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J. Clin. Invest., 91, 1453-1458.
34. SCHUNKERT, H., DZAU, V.J., TANG, S.S., HIRSCH, A.T., APSTEIN, C.S. & LORELL, B.H. (1990). Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. J. Clin. Invest., 86, 1913-1920.
35. SHIOMI, M., SHIRAISHI, M., YATA, T. & ITO, T. (1994). Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient Watanabe heritable hyperlipidemic rabbits. Arzneim.-Forsch./Drug Res., 44, 1154-1156.
36. SHIOTA, N., OKUNISHI, H., FUKAMIZU, A., SAKONJO, H., KIKUMORI, M., NISHIMURA, T., NAKAGAWA, T., MURAKAMI, K. & MIYAZAKI, M. (1993). Activation of two angiotensin-converting Systems in the balloon-injured artery. FEBS Lett., 323, 239-242.
37. TEXTER, M., LEES, R.S., PITT, B., DINSMORE, R.E. & UPRICHARD, A.C.G. (1993). The QUinapril ischemic event trial (QUINT) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention. Cardiovasc. Drugs Ther., 7, 273-282.
38. THE SOLVD INVESTIGATORS. (1992). Effect of enalapril on mortality and the development of heart failure as asymptomatic patients with reduced left ventricular ejection fractions. N. Eng. J. Med., 327, 685-691.
39. WESTLIN, W. & MULLANE, K. (1988). Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation, 77 (Suppl. I), I-30-I-39.